Skip to main content
. Author manuscript; available in PMC: 2023 Apr 3.
Published in final edited form as: Acc Chem Res. 2021 Nov 18;54(23):4283–4293. doi: 10.1021/acs.accounts.1c00550

Figure 2.

Figure 2.

(A) Illustration of mRNA UTR engineering and its application to COVID-19 mRNA vaccines. (B) Serum IgG level in mouse sera post-intramuscular injection. (C) Dosage dependency effects of TT3-NASAR mRNA formulation as a COVID-19 mRNA vaccine.3 Reproduced with permission from ref 3. Copyright 2020 Wiley-VCH.